A2ML1 Inhibits Esophageal Squamous Cell Carcinoma Progression and Serves as a Novel Prognostic Biomarker

Table 1

Association between A2ML1 protein expression and clinicopathological factors.

Factors	Cases (n = 94)	A2ML1 protein expression		value
		Low (n = 48, %)	High (n = 46, %)
Age
<60 years	19	10 (20.83)	9 (19.57)	0.8784
≥60 years	75	38 (79.17)	37 (80.43)
Sex
Female	28	15 (31.25)	13 (28.26)	0.7514
Male	66	33 (68.75)	33 (71.74)
T stage
T1-2	41	13 (31.25)	28 (28.26)	0.0010
T3-4	53	35 (68.75)	18 (71.74)
N stage
N0	57	31 (64.58)	26 (56.52)	0.4239
N+	37	17 (35.42)	20 (43.48)
Differentiation
Well	58	28 (58.33)	30 (65.22)	0.4925
Moderate-poor	36	20 (41.67)	16 (34.78)
Distant metastasis
M0	94	48 (100)	46 (100)
M1	0	0 (0)	0 (0)

, chi-square test. A2ML1, α2-macroglobulin-like 1.